Printed from Voxsanity (voxsanity.com.au) — NCT07590024 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Head And Neck Cancer
Phase 3 Head and Neck Cancer Trial, Recruiting
NCT07590024
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 to 65 years, of any sex
- People who have been diagnosed with a specific type of nasopharyngeal cancer (cancer in the back of the nose/throat) that has been confirmed by a tissue test, is linked to a virus called EBV, is non-spreading, and is of the non-keratinizing type
- People whose cancer is at a certain stage as classified by medical staging systems (AJCC), or who have a particular level of EBV genetic material in their blood above 4,000 copies/mL (confirm with trial site for exact staging details)
- People who are generally well enough to carry out normal daily activities with little or no limitation, as measured by a standard medical scale (score of 0 or 1)
- People who have complete pre-treatment scan results available, including detailed MRI scans of the nasopharynx and neck with specialised imaging sequences, and at least one measurable tumour visible on scans
- People who have had a pre-treatment blood test measuring a specific marker related to EBV in the blood (called cfEBV-DNA)
- People whose blood counts meet specific levels: haemoglobin above 120 g/L and white blood cell count at or above a certain level
- People whose platelet count, liver function, and kidney function are within acceptable ranges, and who have no hearing impairment
- People who are able to understand the study and are willing to sign a written consent form
- People who agree to allow their personal data and biological samples (such as blood and tissue) to be used for research
- People whose major organs are functioning adequately, apart from any effects directly caused by the nasopharyngeal cancer
- People who are able and willing to attend scheduled follow-up appointments
Who may not be able to join:
- People for whom pre-treatment cfEBV-DNA blood test results or other required baseline information are not available
- People whose cancer falls outside the specific staging categories required by this trial (including certain early or advanced stages, or specific tumour and lymph node classifications)
- People who have a history of another cancer, except for certain early-stage skin cancers or a specific pre-cancerous cervical condition
- Women who are pregnant, breastfeeding, or able to become pregnant and not using contraception
- People who are currently taking part in another clinical trial involving an investigational drug
- People with certain serious health conditions, including but not limited to: heart attack history, serious heart rhythm problems, severe stroke-related disease, active stomach ulcers, psychiatric illness, uncontrolled diabetes, active autoimmune disease, current use of immune-suppressing medications, active infections requiring treatment, HIV infection, or certain types of hepatitis B or C infection
- People who are unable to attend regular follow-up visits as required by the trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
Contact this trial
Principal Investigator: Junlin Yi, MD, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phone: +86 18801342502
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Recruiting
Phase
Phase 3
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Registry
ClinicalTrials.gov
Start date
1 May 2026
Est. completion
31 December 2030
Where this trial is recruiting
🇨🇳 China
Primary endpoints
3-year Failure-Free Survival (FFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.